Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410100 | 1.00 | CA2 (0.68) | CA2FFAR1CA1HSD17B2THRA | |
| SCHEMBL8646450 | 0.88 | CA2 (0.62) | CA2CA1HSD17B2IGF1RALOX15 | |
| SCHEMBL1206803 | 0.85 | FFAR1 (0.69) | FFAR1KEAP1FFAR4IGF1RALOX15 | |
| SCHEMBL28022655 | 0.84 | CA2 (0.56) | CA2CA1HSD17B2CYP19A1IGF1R | |
| SCHEMBL22209184 | 0.84 | CA2 (0.56) | CA2CA1HSD17B2CYP19A1IGF1R | |
| Dihydrocaffeic Acid SCHEMBL29351390 | 0.82 | IAPP (0.65) | FFAR1KEAP1CYP19A1IGF1RALOX15 | |
| Dihydrocaffeic Acid SCHEMBL7058919 | 0.82 | IAPP (0.65) | FFAR1KEAP1CYP19A1IGF1RALOX15 | |
| Dihydrocaffeic Acid SCHEMBL245530 | 0.82 | IAPP (0.65) | FFAR1KEAP1CYP19A1IGF1RALOX15 | |
| SCHEMBL9773533 | 0.82 | CA2 (0.61) | CA2CA1HSD17B2IGF1RALOX15 | |
| SCHEMBL9634006 | 0.81 | CNR1 (0.57) | CA2FFAR1CA1KEAP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219939-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-8404836-B2 | 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-26 | — | — | US | disclosed |
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| CN-101679228-A | Novel 3-phenylacrylic acid derivatives as activators of receptors of the PPAR type, method for preparing same and use thereof in cosmetic or pharmaceutical compositions | JEAN-GUY BOITEAU | 2010-03-24 | — | — | CN | disclosed |
| US-20040028749-A1 | Treating inflammation and associated complications | MINNESOTA, REGENTS OF THE UNIVERSITY OF | 2004-02-12 | — | — | US | disclosed |
| WO-2002041885-A2 | TREATMENT OF INFLAMMATION AND ASSOCIATED COMPLICATIONS USING PSEUDOHALIDES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144884-A1 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | CA2 4415/4885FFAR1 5/4885CA1 4877/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | CA2 940/4885FFAR1 3839/4885CA1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.